Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

April Swoner

Nurse Practitioner, Family Hermitage, TN Nurse Practitioner

NPI 1972007201 CMS profile 11200611

5655 Frist Blvd, Hermitage, TN 37076

Open in the dashboard

General payments

$246,466

2,133 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, April Swoner of Hermitage, TN is reported in the CMS Open Payments database as having received $246,466 across 2,133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $80,847 459
2024 General $36,566 425
2023 General $16,304 393
2022 General $45,469 439
2021 General $67,281 417

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • April Swoner
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to April Swoner were reported at $80,847. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year April Swoner Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $67,281 $124 $35–$379 $132
2022 $45,469 $141 $44–$430 $149
2023 $16,304 $154 $49–$476 $160
2024 $36,566 $165 $51–$504 $164
2025 $80,847 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $49,353 309 payments
  2. ACADIA Pharmaceuticals Inc $38,192 92 payments
  3. Biohaven Pharmaceuticals, Inc. $33,090 58 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $25,963 54 payments
  5. ANI Pharmaceuticals, Inc. $25,297 100 payments
  6. Amgen Inc. $15,803 62 payments
  7. Axsome Therapeutics, Inc. $11,968 27 payments
  8. Pfizer Inc. $9,546 54 payments
  9. US WorldMeds, LLC $6,457 83 payments
  10. UCB, Inc. $3,278 97 payments
  11. Other $27,519 1,197 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $155,164 105 payments
  2. Food and Beverage $45,320 1,902 payments
  3. Honoraria $29,332 17 payments
  4. Travel and Lodging $15,194 93 payments
  5. Consulting Fee $1,100 3 payments
  6. Education $356 13 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $59,053 112 payments
  2. UBRELVY $39,202 166 payments
  3. NUPLAZID $38,009 81 payments
  4. PURIFIED CORTROPHIN GEL Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA $19,042 66 payments
  5. AIMOVIG $15,808 62 payments
  6. QULIPTA $14,492 153 payments
  7. Symbravo $11,968 27 payments
  8. NURTEC ODT Pain $8,974 50 payments
  9. PURIFIED CORTROPHIN GEL Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA $6,256 34 payments
  10. BOTOX $5,553 16 payments
  11. Other $34,724 1,433 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

3,028

Median for Nurse Practitioner: 389

Drug cost

$1,288,469

Median for Nurse Practitioner: $21,885

Branded share of claims

33.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 44 $219,346
Ubrelvy Ubrogepant Brand 79 $130,176
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 21 $105,896
Qulipta Atogepant Brand 91 $102,340
Kesimpta Pen Ofatumumab Brand 12 $100,081
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 14 $96,747
Nurtec Odt Rimegepant Sulfate Brand 45 $90,671
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 15 $65,710
Botox Onabotulinumtoxina Brand 48 $63,209
Aimovig Autoinjector Erenumab-Aooe Brand 34 $53,117

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$16,058

Medicare's payments for the services billed

Medicare patients

190

Average age 73

Services billed

263

111 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 40%
Depression 33%
Chronic kidney disease 29%
Ischemic heart disease 26%
Alzheimer's or dementia 21%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 58 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
$12,514 44 —
UBRELVY
$6,063 79 —
PURIFIED CORTROPHIN GEL
$5,373 — —
QULIPTA
$4,515 91 —
Gocovri
$599 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 58 with Patron

Records

2,133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record